

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS
DATED DECEMBER 2, 2025 (THE "RHP"). YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE RHP.**

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID CUM APPLICATION FORM

(IN CASE OF A JOINT BID APPLICATION, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL JOINT BIDDERS. THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE OFFER OF EQUITY SHARES.)

The Equity Shares offered in the Offer have not been and will not be registered, listed or otherwise qualified in any other jurisdiction except India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, outside India except in compliance with the applicable laws of such jurisdiction. On the basis of the Red Herring Prospectus dated December 2, 2025 ("RHP"), which was filed with the Registrar of Companies, Gujarat at Ahmedabad (the "RoC") (if I am/we are in India) or the RHP and the preliminary international wrap dated December 2, 2025 (the "Preliminary International Wrap") and together with the RHP, the "Preliminary Offering Memorandum" (if I am/we are outside India), General Information Document for investing in Public Offers ("GID") and having studied the attached details as per the Abridged Prospectus, I/we hereby apply for Allotment to me/us of the Equity Shares in the Offer up to my/our Bids for maximum number of Equity Shares at or above the Offer Price, to be discovered through the Book Building Process. I/we hereby confirm that I am/we are eligible person(s) to invest in the Offer in accordance with the applicable laws. The amount payable on Bidding has been blocked in the ASBA Account with the relevant SCSS or the bank account linked with the UPI ID (in case of UPI Bidders using UPI Mechanism) as mentioned in the Bid cum Application Form, as the case may be. I/we agree to accept the Equity Shares Bid for, or such lesser number as may be Allotted to me/us subject to the terms of the RHP (if I am/we are in India), Preliminary Offering Memorandum (if I am/we are outside India), Abridged Prospectus, the GID, this Bid cum Application Form and other applicable laws. I/we hereby confirm that I/we do not require approval from any regulatory authority to invest in the Offer according to applicable laws. I/we undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address as given in the Depository records and to place my/our name on the register of members of the Company. I/we acknowledge that in case of QIB Bidders only (i) the SCSSs (for Bids other than the Bids by Anchor Investors) and (ii) the Book Running Lead Managers ("BRLMs") and their respective affiliated Syndicate Members (only in the Specified Locations) have the right to reject Bids (including on technical grounds) at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas it has a right to reject it from Non-Institutional Bidders and Retail Individual Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP or the Preliminary Offering Memorandum, as applicable. I/we authorise the Company to make the necessary changes to the Bid cum Application Form and the RHP for the filing of the Prospectus with the RoC without intimation to me/us and use this Bid cum Application Form as the application form for the purpose of the Offer. I/we confirm that I/we have read a copy of the RHP (if I am/we are in India) or the Preliminary Offering Memorandum (if I am/we are outside India) and will be provided access to the Prospectus (if I am / we are Resident in India) or the Final Offering Memorandum (if I am / we are Resident outside India). I/we confirm that my / our investment decision is solely based on my independent verification and external advice on, the RHP or the Preliminary Offering Memorandum, as applicable and the Prospectus or the Final Offering Memorandum, as applicable.

I/WE CONFIRM THAT I/WE represent, warrant, acknowledge and agree with the Company, the Selling Shareholders and the Members of Syndicate as follows: I am/we are Indian national(s) resident in India and I am/we are not applying for the said Equity Shares as nominees of any person resident outside India or foreign national(s) OR I am/we are Indian national(s) resident in India and I am/we are applying for the said Equity Shares as power of attorney holder(s) of non-resident Indian(s) as mentioned on non-repatriation basis OR I am/we are Indian national(s) resident outside India and I am/we are applying for the said Equity Shares on my/our own behalf through NRO account(s) on non-repatriation basis. (A) I/we have received a copy of the RHP (if I am/we are in India) or the Preliminary Offering Memorandum (if I am/we are outside India) and have read it and our investment decision is based solely on the RHP or the Preliminary Offering Memorandum, as applicable; (B) I/we have read and agree to the representations, warranties, acknowledgements and agreements contained in the section entitled "Offer Procedure" and either (1) the sections "Terms of the Offer" and "Other Regulatory and Statutory Disclosures" of the RHP, if I am/we are in India; or (2) the sections "Distribution and Solicitation Restrictions" and "Transfer Restrictions" of the Preliminary Offering Memorandum, if I am/we are outside India. I/we confirm that I/we and any person I/we represent or the accounts on whose behalf or benefit I/we are purchasing the Equity Shares (A) are either (1) non-U.S. Persons located outside the United States within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act") and are purchasing the Equity Shares in an "offshore transaction" in reliance on Regulation S under the Securities Act ("Regulation S") or (2) located in the United States or are U.S. persons, in each case that are both "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) and "qualified purchasers" (as defined under the U.S. Investment Company Act of 1940) and are purchasing the Equity Shares in transactions exempt from or not subject to the registration requirements of the Securities Act and in reliance on Section 3(c)(7) of the U.S. Investment Company Act; (B) agree to the terms and conditions in (1) of this this Application Form and (2) the RHP, if I am/we are in India, or the Preliminary Offering Memorandum, if I am/we are outside India; (C) if I am/we are making an application to acquire any of the Equity Shares as fiduciary or agent for one or more investor accounts, I/we have sole investment discretion with respect to each such account and I/we have full power to make the foregoing representations, warranties, acknowledgements and agreements on behalf of each such account; (D) I am and each account for which it is purchasing or otherwise acquiring Equity Shares, will purchase, hold or transfer Equity Shares amounting to at least US\$250,000 or its equivalent in another currency; and (E) if I am/we are making an application to acquire any of the Equity Shares for one or more managed accounts, I/we are authorized in writing by each such managed account to subscribe to the Equity Shares for each such managed account and to make (and I/we hereby make) the representations, warranties, acknowledgements and agreements herein for and on behalf of each such account reading the reference to "we" to include such accounts.

FOR QIB BIDDERS: We confirm that the Bid size/maximum Equity Shares applied for by us does not exceed the relevant regulatory approvals/limits. We are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

I/we confirm that I/we are not an affiliate of the Company or a person acting on behalf of such affiliate, and (C) I/we understand that Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Further: (1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and as disclosed in the RHP or the Preliminary Offering Memorandum, as applicable, I/we authorise (a) the members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centers) or the SCSSs (at Designated SCSSs Branches) or the RTAs (at Designated CDP Locations), as the case may be, to do all acts as are necessary to make the application in the Offer, including uploading my/our Bid, blocking, unblocking of funds in the bank account of the applicant maintained with the SCSS as specified in the Bid cum Application Form or in the bank account of the Applicant linked with the UPI ID provided in the Bid cum Application Form, as the case may be, transfer of funds to the Public Offer Account on receipt of instruction from Registrar to the Offer or the Sponsor Banks, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Offer or Sponsor Banks, as the case may be, to issue instruction to the SCSSs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. (2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCSS/Registrar to the Offer shall reject the application. (3) I/we hereby authorise the members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centers) or the SCSSs (at Designated SCSSs Branches) or CDPs (at Designated CDP locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band.

I/we hereby provide my/our consent to the Stock Exchanges / Sponsor Banks / NPCI / Registrar to the Offer for collecting, storing and usage validating my/our PAN details from the bank account where my / our amount is blocked by the relevant SCSSs.

I/we acknowledge that as per existing policy of the Government of India, OCBs cannot participate in the Offer. I am/We are not an OCB. For further details, see "Offer Procedure" and "Restrictions on Foreign Ownership of Indian Securities" beginning on pages 415 and 437 of the RHP, respectively.

INSTRUCTIONS FOR FILLING UP THIS BID CUM APPLICATION FORM

- Name of sole / First Bidder should be exactly the same as it appears in the depository records. In case of joint Bids, only the name of the First Bidder (which should also be the first name in which the beneficiary account is held) should be provided in the Bid cum Application Form. The Bid means an "indication to make an offer" during the Bid/Offer period by a Bidder and not "an offer".
- The First Bidder, should mention his/ her PAN allotted under the Income Tax Act, 1961, DP ID, Client ID and UPI ID (as applicable). Except for Bids by or on behalf of the Central or State Government and the officials appointed by the courts and by investors who are exempt from the requirement of obtaining/ specifying their PAN for transacting in the securities market and by persons residing in the state of Sikkim, any other category of Bidders, including without limitation, multilateral/bilateral development financial institutions, the Bidders, or in the case of joint Bids, the First Bidder (the first name under which the beneficiary account is held), should mention his/ her PAN allotted under the Income Tax Act, 1961. Any Bid cum Application Form without the PAN is liable to be rejected other than as specified above. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with Central Board of Direct Taxes ("CBDT") notification dated February 13, 2020 and press release dated June 25, 2021, read with press release dated September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press releases in this regard.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar to the Offer will obtain Demographic Details registered with Depository Participants to be used, among other things, for Allotment, technical rejections or unblocking ASBA Account. Hence, Bidders are advised to immediately update any change in their Demographic Details as appearing on the records of the Depository Participant to ensure accuracy of records. Please note that failure to do so could result in failure in Allotment of Equity Shares, delays in unblocking of ASBA Account at the Bidders' sole risk and neither the members of the Syndicate nor the Registered Brokers nor the Registrar to the Offer nor RTAs/CDPs nor the SCSSs nor the Company shall have any responsibility and undertake any liability for the same.
- Lot and Price Band:** The face value of Equity Shares is ₹ 10/- each. The Price Band and the minimum Bid Lot size has been decided by the Company in consultation with the Book Running Lead Managers. The Price Band and Minimum Bid Lot size has been advertised in all editions of Financial Express (a widely circulated English national daily newspaper), all editions of Janasatta (a widely circulated Hindi national daily newspaper), and Ahmedabad edition of Jai Hind (a widely circulated Gujarati daily newspaper, Gujarati being the regional language of Gujarat where our Registered Office is located), each with wide circulation, at least two (2) Working Days prior to the Bid/Offer Opening Date, with the relevant financial ratios calculated at the Floor Price and at the Cap Price and has been made available to the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") and together with BSE, the "Stock Exchanges") for the purpose of uploading on their respective websites in accordance with SEBI ICDR Regulations. In case of revision of the Price Band, the Bid/Offer Period will be extended by at least three (3) additional Working Days after such revision of Price Band subject to the Bid/Offer Period not exceeding ten (10) Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, the Company, may, for reasons to be recorded in writing, extend the Bid/Offer Period for a period of minimum one Working Day, subject to the Bid/Offer Period not exceeding ten (10) Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice and also by indicating the changes on the websites of the BRLMs, and at the terminals of the Syndicate Member and by intimation to SCSSs, Designated Intermediaries and the Sponsor Banks as applicable.
- Maximum and Minimum Bid Size:** In case of Retail Individual Bidders, such number of Equity Shares in multiples of the minimum Bid Lot size that the Bid Amount does not exceed ₹ 0.20 million. Bids at the Cut-Off Price indicate their agreement to purchase the Equity Shares at the Offer Price, as determined at the completion of the Book Building Process. In case of Non-Institutional Bidders and QIB Bidders, the minimum Bid size shall be such number of Equity Shares in multiples of the minimum Bid Lot size that Bid Amount exceeds ₹ 0.20 million. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws and mentioned in the RHP or Preliminary Offering Memorandum, as applicable.
- Please tick category as applicable to ensure proper upload of Bid in Stock Exchange system.
- Please tick investor status as applicable. Please ensure investor status is updated in your depository records.
- Cheques/Demand Draft/Cash/Stock in money/other postal orders will not be accepted.** Eligible NRIs bidding on a non-repatriation basis by using the Resident Bid cum Application Form are required to authorise their SCSS to confirm or accept the UPI Mandate Request (in case of UPI Bidders Bidding through the UPI Mechanism) to block their Non-Resident Ordinary (NRO) Accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. All Bidders including the Eligible NRI Bidders Bidding on a repatriation basis by using the Non-Resident Bidders should authorise their SCSS (if they are Bidding directly through the SCSS) or confirm or accept the UPI Mandate Request (in case of Retail Institutional Bidders bidding through the UPI Mechanism) to block their Non-Resident Ordinary ("NRE") accounts (including UPI ID, if activated), or Foreign Currency Non-Resident ("FCNR") Accounts. All Bidders including the Eligible NRI Bidders Bidding on a non-repatriation basis can obtain the Bid cum Application Form from the Registered and Corporate Office of the Company or from any of the members of the Syndicate or CDPs or RTAs or Registered Brokers from the Bidding centers. In accordance with applicable law and Bidders' Instructions, Bidders to please ensure that SCSS where the ASBA Account is maintained has notified at least one branch in the location where Bid cum Application Forms will be deposited by Designated Intermediaries.
- Please note that application made using third party UPI ID or third party ASBA Bank Account are liable to be rejected.
 - QIB cannot apply through UPI mechanism and Non-Institutional Investors bidding for an amount exceeding ₹ 0.5 million cannot use UPI Mechanism to apply. UPI Bidders applying up to ₹ 0.5 million can apply through UPI mode as per NPCI vide circular reference no. NPCI/UP/OC No. 127/2021-22 dated December 9, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
 - For Retail Individual Bidders (RIBs) and Individuals applying as Non-Institutional Bidders with Application size up to ₹ 0.5 million ("UPI Bidders") bidding through the UPI Mechanism.**
 - Please ensure that your bank is offering UPI facility for public offers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) UPI Bidders bidding through the UPI Mechanism may apply through the SCSSs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/otherOtherAction.do?doRecognisedpf=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/otherOtherAction.do?doRecognisedpf=yes&intmid=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.**
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
 - UPI Bidders bidding through the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on page 415 of the RHP.

- Only the Sole Bidder / First Bidder is required to sign the Bid cum Application Form / Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the account holder. Necessary revisions in the Bidders' undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares is proposed.
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the members of the Syndicate, Registered Broker, CDPs, RTAs, and/or SCSSs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms; and c. Ensure that all applicable documents in support of the Bid are attached with the Bid cum Application Form.
- The Bidders may note that the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchanges do not match with the DP ID, Client ID and PAN available in the Depository database. The Bid cum Application Form is liable to be rejected. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022, read with press release dated March 28, 2023 and any subsequent press releases in this regard. You may send the RHP and the Prospectus (if you are Resident in India) or the Preliminary Offering Memorandum and the final offering memorandum (if you are Resident outside India) either in physical form or electric form or both. You shall not distribute or forward this document and these documents are subject to the disclaimers and restrictions contained in or accompanying them.
- This Bid cum Application Form is being offered to you on the basis that you (i) confirm that the representations, warranties, agreements and acknowledgements set out in "Other Regulatory and Statutory Disclosures", "Terms of the Offer" and "Offer Procedure" on pages 389, 402 and 415 respectively of the RHP and agree to abide by (1) this Bid cum Application Form and (2) the RHP (if you are in India) or the Preliminary Offering Memorandum (if you are outside India) together with the terms and conditions contained therein.
- You may send the RHP and the Prospectus (if you are Resident in India) or the Preliminary Offering Memorandum and the final offering memorandum (if you are Resident outside India) either in physical form or electric form or both. You shall not distribute or forward this document and these documents are subject to the disclaimers and restrictions contained in or accompanying them.
- The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any other applicable law of the United States and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons as defined in Regulation S under the U.S. Securities Act ("U.S. Persons") except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold (a) to persons in the United States or to for the account or benefit of, U.S. Persons, in each case that are both "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) and "qualified purchasers" (as defined under the U.S. Investment Company Act) in reliance on Section 3(c)(7) of the U.S. Investment Company Act; or (b) outside the United States to investors that are not U.S. Persons nor persons acquiring for the account or benefit of U.S. Persons in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

Note: Terms used but not defined herein shall have the meaning assigned to such terms in the RHP or the Preliminary Offering Memorandum, as applicable. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is also available on the respective websites of the BRLMs and the Stock Exchanges.

TEAR HERE

COMPANY CONTACT DETAILS		REGISTRAR TO THE OFFER CONTACT DETAILS
CORONA REMEDIES LIMITED Corporate Identity Number: U24231GJ2004PLC044656 Registered and Corporate Office: CORONA House, C – Mondeal Business Park, Near Gurudwara, S. G. Highway, Thaltej, Ahmedabad 380 059, Gujarat, India; Contact Person: Chetna Prabhatkumar Dharajiya, <i>Company Secretary and Compliance Officer;</i> Telephone: +91 79 4023 3000; E-mail: complianceofficer@coronaremedies.com ; Website: www.coronaremedies.com		BIGSHARE SERVICES PRIVATE LIMITED S6-2, 6 th Floor, Pinnacle Business Park, Mahakali Caves Road, Next to Ahura Centre, Andheri (East), Mumbai 400 093, Maharashtra, India Tel: +91 22626 38200 E-mail: ipo@bigshareonline.com Investor Grievance E-mail: investor@bigshareonline.com Website: www.bigshareonline.com Contact Person: Babu Ravepal C. SEBI Registration No.: INR000001385



(Please scan this QR code to view the RHP)

This is an abridged prospectus containing salient features of the red herring prospectus of CORONA Remedies Limited (the “Company”) dated December 2, 2025, (the “RHP” or “Red Herring Prospectus”) filed with the Registrar of Companies, Gujarat at Ahmedabad (the “RoC”). You are encouraged to read greater details available in the RHP, which is available at <https://www.sebi.gov.in/sebiweb/home/HomeAction.do?doListing=yes&sid=3&ssid=15&smid=11>. Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to them in the RHP. This abridged prospectus is not for distribution outside India.

THIS ABRIDGED PROSPECTUS CONSISTS OF FOUR PAGES OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND EIGHT PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.

Please ensure that you have read the RHP (if in India), the preliminary international wrap dated December 2, 2025, (together with the RHP, the “Preliminary Offering Memorandum”) (if outside India), this abridged prospectus (“Abridged Prospectus”) and the general information document for investing in public offer (“GID”) undertaken through the Book Building Process before applying in the Offer (as defined below). The investors are advised to retain a copy of the RHP/Abridged Prospectus for their future reference.

You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchanges (defined below), Members of the Syndicate, Registrar to the Offer, registrar and share transfer agents (“RTAs”), Collecting Depository Participants (“CDPs”), Registered Brokers, Bankers to the Offer, Self Certified Syndicate Banks (“SCSBs”) (each term as defined in the RHP). You may also download the RHP from the website of Securities and Exchange Board of India (“SEBI”) at www.sebi.gov.in, the websites of National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE”) and together with NSE, the “Stock Exchanges”) at www.nseindia.com and www.bseindia.com, respectively the website of the Company at www.coronaremedies.com and the websites of the Book Running Lead Managers at www.jmfl.com, www.iiflcapital.com and <https://investmentbank.kotak.com>, respectively.



CORONA REMEDIES LIMITED

Corporate Identity Number: U24231GJ2004PLC044656; Date of Incorporation: August 27, 2004

Registered and Corporate Office	Contact Person	Email and Telephone	Website
CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej Ahmedabad 380 059, Gujarat, India	Chetna Prabhatkumar Dharajiya <i>Company Secretary and Compliance Officer</i>	Email: complianceofficer@coronaremedies.com Tel: +91 79 4023 3000	www.coronaremedies.com

PROMOTERS OF OUR COMPANY: DR. KIRTIKUMAR LAXMIDAS MEHTA, NIRAVKUMAR KIRTIKUMAR MEHTA AND ANKUR KIRTIKUMAR MEHTA

DETAILS OF THE OFFER TO THE PUBLIC

Type	Fresh Issue size	Offer for Sale size	Total Offer size	Eligibility and reservation	Share Reservation among			
					Qualified Institutional Buyers (“QIBs”) / “QIB Bidders”)	Non-Institutional Bidders (“NIBs”)	Retail Individual Bidders (“RIBs”)	Employee Reservation Portion
Offer for Sale	Not Applicable	Up to [●] Equity Shares of face value of ₹ 10 each aggregating up to ₹ 6,553.71 million	Up to [●] Equity Shares of face value of ₹ 10 each aggregating up to ₹ 6,553.71 million	The Offer is being made pursuant to Regulation 6(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”). For further details, see “Other Regulatory and Statutory Disclosures – Eligibility for the Offer” on page 390 of the RHP. For details in relation to share reservation among Qualified Institutional Buyers, Non-Institutional Investors, Retail Individual Investors and Eligible Employees, see “Offer Structure” on page 409 of the RHP.	Not more than 50% of the Net Offer shall be available to QIBs. 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds.	Not less than 15% of the Net Offer or the Net Offer less allocation to QIBs and NIBs	Not less than 35% of the Net Offer or Net Offer less allocation to QIBs and NIBs will be available for allocation	Up to [●] Equity Shares of face value of ₹ 10 each

The Equity Shares are proposed to be listed on the stock exchanges being National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE”). For the purpose of the Offer, NSE is the Designated Stock Exchange (the “Designated Stock Exchange”).

DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION

Name of the Selling Shareholder	Type of Selling Shareholder	Maximum number of Offered Shares / Amount (₹ in million)	Weighted average cost of acquisition per Equity Share (in ₹)*
Dr. Kirtikumar Laxmidas Mehta	Promoter Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹1,298.41 million	0.10
Minaxi Kirtikumar Mehta	Promoter Group Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹766.07 million	0.08
Dipababen Niravkumar Mehta	Promoter Group Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹103.87 million	1.91
Brinda Ankur Mehta	Promoter Group Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹103.87 million	0.09
Sepia Investments Limited	Investor Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹ 4,046.00 million	408.76
Anchor Partners	Investor Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹151.25 million	408.76
Sage Investment Trust	Investor Selling Shareholder	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹84.24 million	408.76

*As certified by O.R. Maloo & Co., Chartered Accountants, with firm registration number 0135561W, by way of their certificate dated December 2, 2025.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

PRICE BAND, MINIMUM BID LOT & INDICATIVE TIMELINES

Price Band	₹ 1,008 per Equity Share of face value of ₹ 10 each (Floor Price) to ₹ 1,062 per Equity Share of face value of ₹ 10 each (Cap Price).
Minimum Bid Lot Size	A Minimum of 14 Equity Shares and in multiples of 14 Equity Shares thereafter
Anchor Investor Bidding Date	Friday, December 5, 2025
Bid/Offer Opens On	Monday, December 8, 2025
Bid/Offer Closes On ⁽¹⁾	Wednesday, December 10, 2025
Finalisation of Basis of Allotment with the Designated Stock Exchange	On or about December 11, 2025
Initiation of refunds (if any, for Anchor Investors) / unblocking of funds from ASBA Account	On or about December 12, 2025
Credit of Equity Shares to Demat accounts of Allottees	On or about December 12, 2025
Commencement of trading of the Equity Shares on the Stock Exchanges	On or about December 15, 2025

⁽¹⁾ UPI mandate end time and date shall be at 5:00 pm on the Bid/Offer Closing Date.

For details of the Price Band and the basis for the Offer Price, please refer to the price band advertisement and the section titled “Basis for Offer Price” on page 126 of the RHP.

WEIGHTED AVERAGE COST OF ACQUISITION OF ALL EQUITY SHARES TRANSACTED IN LAST ONE YEAR, 18 MONTHS AND THREE YEARS PRECEDING THE DATE OF THE RED HERRING PROSPECTUS

Period	Weighted average cost of acquisition (in ₹) ⁽¹⁾	Cap Price is ‘x’ times the weighted average cost of acquisition	Range of acquisition price: lowest price – highest price (in ₹) ⁽¹⁾
Last one year preceding the date of this Red Herring Prospectus	-	-	-
Last 18 months preceding the date of this Red Herring Prospectus	0.09	11,800.00	Nil – 0.14
Last three years preceding the date of this Red Herring Prospectus	0.09	11,800.00	Nil – 0.14

⁽¹⁾ As certified by O.R. Maloo & Co., Chartered Accountants, with firm registration number 0135561W, by way of their certificate dated December 2, 2025.

The Equity Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold outside the United States in “offshore transactions”, as defined in, and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

RISKS IN RELATION TO THE FIRST OFFER

This being the first public offer of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹10. The Offer Price/ Floor Price/ Cap Price, as determined and justified by our Company, in consultation with the BRLMs in accordance with the SEBI ICDR Regulations and as stated in “Basis for Offer Price”, beginning on page 126, should not be taken to be indicative of the market price of the Equity Shares after such Equity Shares are listed. No assurance can be given regarding an active and/ or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to “Risk Factors” on page beginning on page 30 of the RHP.

PROCEDURE

You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchanges, Members of the Syndicate, Registrar to the Offer, RTAs, CDPs, Registered Brokers, Bankers to the Offer, Investors’ Associations or SCSBs.

If you wish to know about processes and procedures applicable to the Offer, you may request for a copy of the RHP and/or the GID from the BRLMs or download it from the website of SEBI at www.sebi.gov.in, the websites of NSE and BSE at www.nseindia.com and www.bseindia.com, respectively, and the websites of the BRLMs at i.e., at www.jmfml.com, www.iiflcapital.com and <https://investmentbank.kotak.com>, respectively..

PAST PRICE INFORMATION OF BRLMS

Sr. No.	Issue name	BRLM Name	+/- % change in closing price, [+/- % change in closing benchmark] - 30 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark] - 90 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark] - 180 th calendar days from listing
1.	Capillary Technologies India Limited	JM, IIFL	Not Applicable	Not Applicable	Not Applicable
2.	Tenneco Clean Air India Limited	JM	Not Applicable	Not Applicable	Not Applicable
3.	Emmvee Photovoltaic Power Limited	JM, IIFL, Kotak	Not Applicable	Not Applicable	Not Applicable
4.	Studds Accessories Limited	IIFL	Not Applicable	Not Applicable	Not Applicable
5.	Canara HSBC Life Insurance Company Limited	JM	13.50% [0.78%]	Not Applicable	Not Applicable
6.	Rubicon Research Limited	JM, IIFL	+47.18%, [+1.27%]	Not Applicable	Not Applicable
7.	Tata Capital Limited	IIFL, Kotak	-0.11%, [+1.85%]	Not Applicable	Not Applicable
8.	Seshaasai Technologies Limited	IIFL	-11.45%, [+5.89%]	Not Applicable	Not Applicable
9.	Sudeep Pharma Limited	IIFL	Not Applicable	Not Applicable	Not Applicable
10.	Canara Robeco Asset Management Limited	JM	9.81% [1.27%]	Not Applicable	Not Applicable
11.	Wework India Management Limited	JM, Kotak	-2.48% [0.82%]	Not Applicable	Not Applicable
12.	Urban Company Limited	JM, Kotak	53.83% [1.01%]	Not Applicable	Not Applicable
13.	Vikram Solar Limited	JM	-1.48% [1.40%]	-13.25% [5.49%]	Not Applicable
14.	JSW Cement Limited	JM, Kotak	1.17% [1.96%]	-16.64% [4.32%]	Not Applicable

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

15.	Physicwallah Limited	Kotak	Not applicable	Not applicable	Not applicable
16.	Billionbrains Garage Ventures Limited	Kotak	Not applicable	Not applicable	Not applicable
17.	Lenskart Solutions Limited	Kotak	Not applicable	Not applicable	Not applicable
18.	Orkla India Limited	Kotak	Not applicable	Not applicable	Not applicable
19.	Bluestone Jewellery and Lifestyle Limited	Kotak, IIFL	+15.13%, [+1.40%]	+11.17%, [+3.72%]	Not applicable

Source: www.nseindia.com and www.bseindia.com

For further details, please refer to Other Regulatory and Statutory Disclosures - Price information of past issues handled by the Book Running Lead Managers on page 396 of the RHP

BOOK RUNNING LEAD MANAGERS

JM Financial Limited Tel: +91 22663 03030 E-mail: corona.ipo@jmfml.com Investor Grievance E-mail: grievance.ibd@jmfml.com	IIFL Capital Services Limited (formerly known as IIFL Securities Limited) Tel: +91 22464 64728; E-mail: corona.ipo@iiflcap.com Investor Grievance E-mail: ig.ib@iiflcap.com	Kotak Mahindra Capital Company Limited Tel: +91 22433 60000 E-mail: coronaremedies.ipo@kotak.com Investor Grievance E-mail: kmccredressal@kotak.com
--	--	--

Name of Syndicate Members	Kotak Securities Limited and JM Financial Services Limited
Name of Registrar to the Offer	Bigshare Services Private Limited Tel: +91 22626 38200; E-mail: ipo@bigshareonline.com ; Investor Grievance E-mail: investor@bigshareonline.com
Name of Statutory Auditors	Deloitte Haskins & Sells LLP, Chartered Accountants
Name of Credit Rating Agency and the rating or grading obtained, if any	As this is an Offer of Equity Shares, credit rating is not required
Name of Debenture Trustee	Not applicable
Self Certified Syndicate Bank(s) and mobile applications enabled for UPI Mechanism	In accordance with SEBI ICDR Master Circular and SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, UPI Bidders Bidding using the UPI Mechanism may only apply through the SCSBs and mobile applications whose names appears on the website of the SEBI, i.e., (www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40) for SCSBs and (www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43) for mobile applications, respectively, as updated from time to time. A list of SCSBs and mobile applications, which are live for applying in public issues using UPI Mechanism is available on (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40) and (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43).
Self-Certified Syndicate Bank(s) or SCSB(s)	The banks registered with SEBI, which offer the facility of ASBA services, (i) in relation to ASBA, where the Bid Amount will be blocked by authorising an SCSB, a list of which is available on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 and updated from time to time and at such other websites as may be prescribed by SEBI from time to time, (ii) in relation to UPI Bidders using the UPI Mechanism, a list of which is available on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 and updated from time to time and at such other websites as may be prescribed by SEBI from time to time, and (ii) The banks registered with SEBI, enabled for UPI Mechanism, a list of which is available on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 or such other website as updated from time to time.
Syndicate SCSB Branches	In relation to Bids (other than Bids by Anchor Investors and RIIs) submitted under the ASBA process to a member of the Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI at http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes&intmId=35 , which may be updated from time to time or any such other website as may be prescribed by SEBI from time to time.
Registered Brokers	Bidders can submit ASBA Forms in the Offer using the stockbroker network of the Stock Exchanges, i.e., through the Registered Brokers at the Broker Centres. The list of the Registered Brokers eligible to accept ASBA Forms, including details such as postal address, telephone number and e-mail address, is provided on the websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com , respectively, as updated from time to time.
Details regarding website address(es)/ link(s) from which the investor can obtain a list of RTAs, CDPs and stock brokers who can accept applications from investors, as applicable	The list of the RTAs eligible to accept ASBA Forms at the Designated RTA Locations, including details such as address, telephone number and e-mail address, is provided on the websites of the BSE and NSE at www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx? and www.nseindia.com/products/content/equities/ipos/asba_procedures.htm , respectively, as updated from time to time. The list of the CDPs eligible to accept ASBA Forms at the Designated CDP Locations, including details such as their name and contact details, is provided on the websites of the Stock Exchanges at www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx? and www.nseindia.com/products/content/equities/ipos/asba_procedures.htm , respectively, as updated from time to time. For further details, see “Offer Procedure” on page 415 of the RHP.

THE PROMOTERS OF OUR COMPANY

Sr. No.	Name	Individual/ Corporate	Experience and Educational Qualification
1	Dr. Kirtikumar Laxmidas Mehta	Individual	He has been associated with our Company since incorporation. He holds a bachelor's degree in medicine and surgery from Gujarat University, Ahmedabad, Gujarat. He has over 36 years of experience in the medical and pharmaceutical industry.
2	Niravkumar Kirtikumar Mehta	Individual	He has been associated with our Company since May 30, 2007. He holds a diploma in pharmacy from Saurashtra University, Rajkot, Gujarat and a bachelor's degree in pharmacy from University of Pune, Pune, Maharashtra. He has 20 years of experience in the strategic management, pharmaceutical research and marketing. He has received 2024 Hurun Industry Achievement Award - Pharmaceuticals in 2025 presented by Hurun India.
3	Ankur Kirtikumar Mehta	Individual	He has been associated with our Company since incorporation. He holds a bachelor's degree in science from Saurashtra University, Rajkot, Gujarat and a master's degree in business administration from Gujarat University, Ahmedabad, Gujarat. He has 20 years of experience in the pharmaceutical industry.

For details in respect of the Promoter, please see the section entitled titled “Our Promoter and Promoter Group” beginning on page 278 of the RHP.

OUR BUSINESS OVERVIEW AND STRATEGY

Company Overview: We are an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. According to the CRISIL Intelligence Report. We are the fastest growing company among the top 30 companies in the Indian Pharmaceutical Market (“IPM”) in terms of domestic sales in the IPM, between MAT June 2024 and MAT June 2025. During this period, our domestic sales grew at a CAGR of 13.58% compared to the IPM which grew at a CAGR of 7.90% (Source: CRISIL Intelligence Report).

Product/Service Offering: Our diversified product portfolio comprises 71 brands catering to a range of therapeutic areas such as women's healthcare, cardio-diabeto, pain management and urology and others/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (“VMN”), gastrointestinal and respiratory), as of June 30, 2025. Of our targeted therapeutic areas, our women's healthcare segment contributed to 28.56% (or ₹4,080.26 million), cardio-diabeto (comprising cardio-vascular and anti-diabetic areas) contributed 23.38% (or ₹3,339.96 million), pain management contributed 11.79% (or ₹1,684.38 million) and urology contributed 4.53% (or ₹646.65 million) to our domestic sales for MAT June 2025.

Domestic sales attributable to each of our therapeutic areas

Therapeutic Area	For MAT							
	June 2025		June 2024		June 2023		June 2022	
	Amount (₹ in millions)	% of domestic sales	Amount (₹ in millions)	% of domestic sales	Amount (₹ in millions)	% of domestic sales	Amount (₹ in millions)	% of domestic sales
Women's healthcare	4,080.26	28.56%	3,489.78	27.75%	3,114.22	28.26%	2,322.11	25.88%
Cardio-diabeto	3,339.96	23.38%	2,963.95	23.57%	2,366.69	21.48%	1,841.75	20.53%
Pain Management	1,684.38	11.79%	1,345.06	10.69%	1,069.27	9.70%	994.43	11.08%
Urology	646.65	4.53%	267.26	2.13%	194.30	1.76%	159.17	1.77%
Others	4,533.64	31.74%	4,510.68	35.87%	4,276.13	38.80%	3,654.05	40.73%
Total	14,284.89	100.00%	12,576.74	100.00%	11,020.62	100.00%	8,971.51	100.00%

Notes: The Company's addressable market includes sales for selected subgroups mentioned in the CRISIL Intelligence Report.

1. The women's healthcare market includes subgroups from gynaecological, cardiac, blood related, anti-diabetic vitamins / minerals / nutrients, gastro intestinal, anti-neoplastics, anti-infectives, pain / analgesics and derma. 2. The cardio-diabeto market includes subgroups from anti diabetic, cardiac, blood related, pain / analgesics and hormones. 3. The pain-management market includes subgroups from neuro / CNS and pain / analgesics. 4. The urology market includes subgroups from urology, sex stimulants / rejuvenators and hormones. 5. The others market consists of sales from all the subgroups excluding subgroups mentioned in the above categories.

Source: CRISIL Intelligence Report; see "Industry Overview – Review of competition in the IPM – Trend in therapy wise domestic sales in CORONA's addressable market in the IPM" on page 188.

Geographies Served: Our presence spans over 20 countries, including India, the United Arab Emirates, Uzbekistan, Philippines, Kenya, Cyprus and others, where we employ a calibrated and market-specific approach that takes into account regulatory landscapes, market size, competitive environments, and product demand in each region.

Revenue segmentation by geographies:

Set out below is a breakdown of our revenue from operations by geography for the periods and financial years indicated:

Particulars	Three months ended June 30, 2025		Financial Year					
			2025		2024		2023	
	Amount (in ₹ million)	% of revenue from operations	Amount (in ₹ million)	% of revenue from operations	Amount (in ₹ million)	% of revenue from operations	Amount (in ₹ million)	% of revenue from operations
Revenue from operations – within India	3,338.54	96.34%	11,524.56	96.33%	9,802.28	96.62%	8,521.61	96.39%
Revenue from operations – outside India	126.88	3.66%	439.59	3.67%	342.46	3.38%	318.89	3.61%
Total revenue from operations	3,465.42	100.00%	11,964.15	100.00%	10,144.74	100.00%	8,840.50	100.00%

Key Performance Indicators:

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of Directors of our Company) until one year after the date of listing of the Equity Shares on the Stock Exchanges or for such other duration as may be required under the SEBI ICDR Regulations.

(₹ in million, unless mentioned otherwise)

Particulars	Unit	As of and for the three months ended June 30, 2025	As of and for the Financial Year		
			2025	2024	2023
Revenue from operations	₹ in million	3,465.42	11,964.15	10,144.74	8,840.50
Growth of revenue from operations	%	NA	17.93%	14.75%	NA
Revenue from operations – domestic (as a percentage of total revenue from operations)	%	96.34%	96.33%	96.62%	96.39%
Revenue from operations – international (as a percentage of total revenue from operations)	%	3.66%	3.67%	3.38%	3.61%
Revenue from operations – owned manufacturing (as a percentage of total revenue from operations)	%	62.75%	64.01%	64.52%	62.02%
Gross Profit	₹ in million	2,807.62	9,599.04	7,876.46	6,730.96
Growth of Gross Profit	%	NA	21.87%	17.02%	NA
Gross Profit Margin	%	81.02%	80.23%	77.64%	76.14%
EBITDA	₹ in million	717.96	2,459.13	1,611.90	1,350.30
Growth of EBITDA	%	NA	52.56%	19.37%	NA
EBITDA Margin	%	20.72%	20.55%	15.89%	15.27%
Profit after tax	₹ in million	461.96	1,494.34	905.03	849.29
Growth of PAT	%	NA	65.11%	6.56%	NA
PAT Margin (%)	%	13.33%	12.49%	8.92%	9.61%
Return on Capital Employed (RoCE)	%	11.28%*	41.32%	31.19%	28.36%
Adjusted Return on Capital Employed (Adj. RoCE)	%	14.53%*	47.87%	37.53%	36.62%
Return on Equity (RoE)	%	7.61%*	27.50%	20.36%	23.29%
OCF / EBITDA	%	35.33%#	77.46%	97.25%	76.06%
Net Working Capital Days	Days	68.62**	24.17	23.43	31.20
Net Debt / (Net Cash)	₹ in million	(179.99)	(66.40)	621.20	(952.47)

For further details, please refer to "Basis for Offer Price - Key Performance Indicators" on page 129 of the RHP.

Client Profile or Industries Served: We have a diverse customer base, comprising pharmacies, specialty treatment facilities, other outpatient clients, physicians and hospitals.

Intellectual Property: We rely on a range of trademarks and other proprietary rights, such as trade secrets, know-how and confidentiality agreements to develop, maintain and strengthen our competitive position. In addition, we seek copyright protection of our packaging and labels. We have registered 194 trademarks with 29 applications for trademarks currently pending approval, and 67 of our trademarks have been opposed or objected to. Also see "Risk Factors – As of June 30, 2025, with a portfolio of 71 brands, we held 194 registered trademarks, with 29 pending trademark applications and 67 opposed/ objected/ refused / abandoned trademarks under certain classes of trademarks. If we are unable to obtain trademarks for our products and brands or protect other proprietary information, our business, results of operations, financial condition and cash flows may be adversely affected" on page 36 of the RHP.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Market Share: We are the 17th largest by market share in our Covered Market based on domestic sales for MAT June 2025, and were the third fastest growing Indian pharmaceutical company in terms of prescriptions in targeted specialties (among consultant physicians, cardiologists, diabetologists, gynaecologists, orthopaedics and urologists) between MAT June 2022 and 2025. We are ranked 7th among top 30 players in IPM in terms of increase in market share from MAT June 2022 to MAT June 2025 (Source: *CRISIL Intelligence Report*).

Manufacturing Plant: We operate two manufacturing facilities, located in the states of Gujarat and Himachal Pradesh and are in the process of commissioning a hormone manufacturing facility in the state of Gujarat.

Employee Strength: As of June 30, 2025, we had 4,573 permanent employees.

BOARD OF DIRECTORS

Sr. No.	Name	Designation	Experience & Educational Qualification	Directorships in other companies
1.	Dr. Kirtikumar Laxmidas Mehta	Chairman and Non-Executive Director	He holds a bachelor's degree in medicine and surgery from Gujarat University, Ahmedabad, Gujarat. He has over 36 years of experience in the medical and pharmaceutical industry.	<i>Indian Companies:</i> Nil <i>Foreign Companies:</i> Nil
2.	Niravkumar Kirtikumar Mehta	Managing Director and Chief Executive Officer	He holds a diploma in pharmacy from Saurashtra University, Rajkot, Gujarat and a bachelor's degree in pharmacy from University of Pune, Pune, Maharashtra. He has 20 years of experience in the strategic management, pharmaceutical research and marketing. He has received 2024 Hurun Industry Achievement Award - Pharmaceuticals in 2025 presented by Hurun India.	<i>Indian Companies:</i> Nil <i>Foreign Companies:</i> Nil
3.	Ankur Kirtikumar Mehta	Joint Managing Director	He holds a bachelor's degree in science from Saurashtra University, Rajkot, Gujarat and a master's degree in business administration from Gujarat University, Ahmedabad, Gujarat. He has 20 years of experience in the pharmaceutical industry.	<i>Indian Companies:</i> Nil <i>Foreign Companies:</i> Nil
4.	Viral Bhupendrabhai Sitwala	Whole-Time Director	He holds a diploma in pharmacy from Saurashtra University, Rajkot, Gujarat. He is responsible for overall operation and quality function for all the manufacturing plants of the Company. He has 20 years of experience in the pharmaceutical industry. He was previously associated with FDC Limited and American Remedies Limited.	<i>Indian Companies:</i> Nil <i>Foreign Companies:</i> Nil
5.	Ameetkumar Hiranyakumar Desai	Independent Director	He holds a bachelor's degree in business administration from Sardar Patel University, Anand, Gujarat. He also holds a master's degree in business administration with specialisation in finance from Gujarat University, Ahmedabad, Gujarat. He has completed the leading and managing people program certified from and by The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania, United States. He currently serves on the board of directors of Adani Aerospace and Defence Limited, Ambuja Cements Limited, Adani Defence Systems and Technologies Limited, Adani Naval Defence Systems and Technologies Limited, and JM Financial Asset Reconstruction company Limited. He has over 19 years of experience across pharmaceutical, defence and finance industries.	<i>Indian Companies:</i> 1. Adani Aerospace and Defence Limited; 2. Adani Defence Systems and Technologies Limited; 3. Adani Naval Defence Systems and Technologies Limited; 4. Ambuja Cements Limited; 5. Ganesh Housing Corporation Limited; 6. Hester Biosciences Limited; 7. JM Financial Asset Reconstruction Company Limited; 8. Nxgn Sports Interactive Private Limited; and 9. Sourcepro Infotech Private Limited. <i>Foreign Companies:</i> Nil
6.	Monica Hemal Kanuga	Independent Director	She holds a bachelor's degree in commerce from Gujarat University, Ahmedabad, Gujarat. She also holds a bachelor's degree in law (general) and a bachelor's degree in law (special) from Gujarat University, Ahmedabad, Gujarat. She is registered as, an insolvency professional with Insolvency and Bankruptcy Board of India and Insolvency Professionals Agency, and a company secretary from the Institute of Company Secretaries of India. She has over 30 years of experience in corporate compliance and governance.	<i>Indian Companies:</i> Nil <i>Foreign Companies:</i> Nil
7.	Shirish Gundopant Belapure	Independent Director	He holds a bachelor's degree in pharmacy from Shivaji University, Kolhapur, Maharashtra. He also holds a master's degree in pharmacy (pharmacognosy) from Nagpur University, Nagpur, Maharashtra. He has also completed a long-term diploma course in business management from the Nagpur Management Association, Nagpur, Maharashtra. He was previously associated with Zydus Hospira Oncology Private Limited as the managing director, Zydus Lifesciences Limited as the president – manufacturing (formulations), and was also associated with Cipla Limited, Sun Pharmaceuticals Industries Limited, M. J. Pharmaceuticals Limited, The Fairdeal Corporation (Private) Limited, Griffon Laboratoires Private Limited and Cyanamid India Limited. He has over 17 years of experience in the pharmaceutical industry.	<i>Indian Companies:</i> 1. Innova Captab Limited; 2. Jubilant Pharmova Limited; 3. Jubilant Generics Limited; 4. Natural Capsules Limited; and 5. Uniza Lifecare Private Limited. <i>Foreign Companies:</i> Nil

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Sr. No.	Name	Designation	Experience & Educational Qualification	Directorships in other companies
8.	Bhaskar Vemban Iyer	Independent Director	He holds a bachelor's degree in science and a master's degree in marketing management, both from University of Bombay, Mumbai, Maharashtra. He was previously associated with Abbott Healthcare Private Limited, Advent Pharma Limited and Quadria Capital. He has over 14 years of experience across in the pharmaceutical and healthcare industry.	<i>Indian Companies:</i> 1. RPG Lifesciences Limited; and 2. Themis Medicare Limited. <i>Foreign Companies:</i> Nil

For further details in relation to our Board of Directors, see “Our Management” beginning on page 260 of the RHP.

OBJECTS OF THE OFFER

The objects of the Offer are to achieve the benefits of listing the Equity Shares on the Stock Exchanges and for the Offer for Sale of up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹6,553.71 million. Each Selling Shareholder has, severally and not jointly, authorised its participation in the Offer for Sale to the extent of its respective portion of the Offered Shares, pursuant to its respective consent letter. Set forth hereunder are the details of the number of Equity Shares offered by each of the Selling Shareholders in the Offer:

Name of the Selling Shareholder	Maximum number of Offered Shares/ Amount (in ₹ million)
Dr. Kirtikumar Laxmidas Mehta	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹1,298.41 million
Minaxi Kirtikumar Mehta	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹766.07 million
Dipabehen Niravkumar Mehta	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹103.87 million
Brinda Ankur Mehta	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹103.87 million
Sepia Investments Limited	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹4,046.00 million
Anchor Partners	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹151.25 million
Sage Investment Trust	Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹84.24 million

For further details, see “The Offer” on page 86 of the RHP.

Our Company expects that listing of the Equity Shares will enhance our visibility and brand and provide liquidity to its existing Shareholders. Listing will also provide a public market for the Equity Shares in India.

Utilization of the Offer Proceeds

Our Company will not receive any proceeds from the Offer (“Offer Proceeds”) and the Offer Proceeds will be received by the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholders as part of the Offer after deducting their portion of the Offer related expenses and the relevant taxes thereon. See “The Offer” and “Other Regulatory and Statutory Disclosures” on pages 86 and 389, respectively.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilisation of issue proceeds of past public offers / rights issues, if any, of our Company in the preceding 10 years: Not applicable.

Terms of Issuance of Convertible Security, if any: Not applicable.

Name of Monitoring Agency: Not applicable.

Shareholding Pattern as on the date of the RHP:

Category of shareholder	Pre-Offer number of fully paid-up Equity Shares of face value of ₹10 each	% Holding of pre-Offer Equity Share capital
Promoters and Promoter Group	44,338,558	72.50%
Public	16,821,530	27.50%
Total	61,160,088	100.00%

Number/ amount of Equity Shares proposed to be sold by the Selling Shareholders: Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹6,553.71 million.

SUMMARY OF THE RESTATED FINANCIAL INFORMATION

The summary of selected financial information of our Company derived from the Restated Consolidated Financial Information is set forth below:

(₹ in million, unless otherwise specified)

Particulars	As at and for the three months ended June 30, 2025	As at and for the year ended March 31, 2025	As at and for the year ended March 31, 2024	As at and for the year ended March 31, 2023
Equity share capital	611.60	611.60	611.60	611.60
Net Worth	6,070.24	6,063.44	4,804.07	4,085.20
Revenue from operations	3,465.42	11,964.15	10,144.74	8,840.50
Profit after tax	461.96	1,494.34	905.03	849.29
Earnings per share (in ₹)	7.55*	24.43	14.80	14.57
Net Asset Value per Equity Share (in ₹)	99.25	99.14	78.55	70.06
Total borrowings	1,066.48	626.95	1,341.42	23.31

For further details, see “Restated Consolidated Financial Information” and “Other Financial Information” beginning on pages 283 and 339, respectively, of the RHP.

INTERNAL RISK FACTORS

Below mentioned risks are the top 5 risk factors as per the RHP. For further details, see “Risk Factors” on page 30 of the RHP.

- The therapeutic areas of women's healthcare, cardio-diabeto and pain management contributed to an aggregate of ₹2,257.26 million (or 65.14%) and ₹7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

2. Our 27 “engine” brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our “engine” brands could have an adverse effect on our business, results of operations, financial condition and cash flows.
3. We derive a significant majority of our revenue from our operations within India (constituting 96.34% and 96.33% of our revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for our products in India, or if we fail to successfully expand into international markets, our business, results of operations, financial conditions and cash flows may be adversely affected.
4. A significant portion of our domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh (accounting for 47.30% of our domestic sales for MAT June 2025). Any adverse developments affecting our sales in these regions could have an adverse effect on our business, results of operations, financial condition and cash flows.
5. 70.10% of our domestic sales for MAT June 2025 were derived from chronic and sub-chronic therapeutic segments, which are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and cash flows.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

- A. A summary of outstanding litigation proceedings involving our Company, our Directors, our Promoters, our Key Managerial Personnel, our Senior Management and our Group Company, as disclosed in this Red Herring Prospectus, is provided below:

Category of individuals/ entities	Criminal proceedings	Tax proceedings	Statutory or regulatory actions	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters in the last five years, including outstanding action	Material civil litigations as per the Materiality Policy	Aggregate amount involved* (in ₹ million)
Company						
By our Company	4	Nil	N.A	N.A	1	0.44
Against our Company	Nil	Nil	6 [#]	N.A	Nil	Nil
Directors						
By our Directors	Nil	Nil	N.A	N.A	Nil	Nil
Against our Directors	Nil	9 [^]	7 [#]	N.A	Nil	16.98
Promoters						
By our Promoters	Nil	Nil	N.A	N.A	Nil	Nil
Against our Promoters	Nil	9 [^]	6 [#]	Nil	Nil	16.98
Key Managerial Personnel						
By our Key Managerial Personnel	Nil	N.A	N.A	N.A	N.A	Nil
Against our Key Managerial Personnel	Nil	N.A	6 [#]	N.A	N.A	Nil
Senior Management						
By our Senior Management	Nil	N.A	N.A	N.A	N.A	Nil
Against our Senior Management	Nil	N.A	Nil	N.A	N.A	Nil

* To the extent quantifiable.

[^] Includes the matters against Directors who are also Promoters.

[#] Includes the matters against the Company, which also involved the Directors, who are Promoters and KMPs of the Company as well.

Further, there are no outstanding litigation proceedings involving our Group Company, the adverse outcome of which may have a material impact on our Company.

For further details of the outstanding litigation proceedings, see “Outstanding Litigation and Material Developments” on page 378 of the RHP.

- B. Brief details of pending other material outstanding litigations against the Company and amount involved:

Sr. No.	Particulars	Litigation filed by	Current Status	Amount involved
1.	The Drugs Inspector, Central Drugs Standard Control Organisation, West Zone, Mumbai filed a complaint dated July 21, 2020, (“ Complaint ”), before the court of the Judicial Magistrate First Class, Ulhasnagar, Maharashtra (“ District Court ”), under Sections 18(a)(i), 16, 34 and 27(d) of the Drugs and Cosmetics Act, 1940, as amended, (“ Drugs and Cosmetics Act ”) against our Company, certain of our Directors, namely Viral Bhupendrabhai Sitwala, Ankur Kirtikumar Mehta and Dr. Kirtikumar Laxmidas Mehta and certain of our Shareholders, namely Brinda Mehta and Minaxi Mehta (together, the “ Defendants ”), alleging that certain products containing a drug COR-3 manufactured by us, are not of standard quality, in contravention of the Drugs and Cosmetics Act. The District Court, pursuant to its order dated February 28, 2022 (“ Impugned Order ”), issued the process against the Defendants, holding them responsible for the conduct of the business of the Company.	The Drugs Inspector, Central Drugs Standard Control Organisation, West Zone	The Defendants, including our Company filed a criminal application dated August 2, 2024, before the High Court of Judicature at Mumbai (“ Mumbai High Court ”) under Section 482 of the Code of Criminal procedure, 1973, praying for the quashing and setting aside of the Complaint as well as the Impugned Order. The matter is currently pending.	-
2.	Drugs Inspector, Central Drugs Standard Control Organisation, West Zone, Mumbai filed a complaint dated July 21, 2020 (“ Complaint ”), before the court of the Judicial Magistrate First Class, Ulhasnagar, Maharashtra (“ District Court ”), under Sections 18(a)(i), 16, 34 and 27(d) of the Drugs and Cosmetics Act, 1940, as amended, (“ Drugs and Cosmetics Act ”) against our Company, certain of our Directors, namely Viral Bhupendrabhai Sitwala, Ankur Kirtikumar Mehta and Dr. Kirtikumar Laxmidas Mehta and certain of our Shareholders, namely Brinda Mehta and Minaxi Mehta (together, the “ Defendants ”), alleging that certain products containing a drug B-29 manufactured by us, are not of standard quality, in contravention of the Drugs and Cosmetics Act. The District Court, pursuant to its order dated February 28, 2022 (“ Impugned Order ”), issued the process against the Defendants, holding them responsible for the conduct of the business of the Company.	The Drugs Inspector, Central Drugs Standard Control Organisation, West Zone	The Defendants, including our Company filed a criminal application dated August 2, 2024, before the High Court of Judicature at Mumbai (“ Mumbai High Court ”) under Section 482 of the Code of Criminal procedure, 1973, praying for the quashing and setting aside of the Complaint as well as the Impugned Order. The matter is currently pending.	-

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

3.	The Drugs Inspector, Solapur, Food and Drug Administration, Maharashtra filed a complaint dated August 27, 2012 before the Court of the Chief Judicial Magistrate, Solapur, Maharashtra, under Section 17(B)(d), 17(b), 18(a)(i), 18(a)(iv), 27(c) and 27(d) of the Drugs and Cosmetics Act, 1940, as amended, (" Drugs and Cosmetics Act ") and the rules thereunder, against our Company, our Director Viral Bhupendrabhai Sitwala and certain of our employees, alleging manufacture of certain drugs which were spurious in nature and misbranded, leading to a violation of the relevant provisions of the Drugs and Cosmetics Act.	Drugs Inspector, Solapur, Food and Drug Administration, Maharashtra	The matter is currently pending.	-
4.	The Drug Inspector, Jhansi, Food Safety and Drugs Administration, Uttar Pradesh, filed a complaint dated July 1, 2021 (" Complaint ") before the court of the Additional District and Sessions Judge, Jhansi, Uttar Pradesh, under Section 17A, 18(a)(i), 27(b)(i) and 27(d) of the Drugs and Cosmetics Act, 1940, as amended, (" Drugs and Cosmetics Act ") and the rules thereunder, against our Company, our Directors Ankur Kirtikumar Mehta, Dr. Kirtikumar Laxmidas Mehta and Viral Bhupendrabhai Sitwala, our Shareholders Vrinda Mehta and Minaxi Mehta, and certain others alleging manufacture and sale of low quality/ substandard drugs.	Drug Inspector, Jhansi, Food Safety and Drugs Administration, Uttar Pradesh	During the pendency of the matter, our Company filed an application dated November 20, 2021 under Section 482 of the Code of Criminal Procedure, 1973, before the High Court of Judicature at Allahabad, praying for the quashing of the proceedings arising from the Complaint and a summoning order dated July 22, 2021 passed by the Additional District and Sessions Judge, Jhansi, Uttar Pradesh. The High Court of Judicature at Allahabad has, by way of an order dated May 25, 2022, directed that no coercive action shall be taken against the Company until the next date of listing. The matter is currently pending.	-
5.	The State of Bihar through Drug Inspector, Muzaffarpur, Drugs Control Administration, filed a complaint dated January 11, 2022 (" Complaint ") before the court of the Special Judge Drugs and Cosmetics Act, Muzaffarpur, against our Company, certain of our Directors and the erstwhile company secretary of our Company, for violations of rules 74, 80 and 83 of the New Drugs and Clinical Trials Rules, 2019, as amended read with Section 18(a)(vi) and 18B of the Drugs and Cosmetics Act, 1940, as amended (" Drugs and Cosmetics Act "), alleging irrationality and non-compliance with applicable laws pertaining to the manufacture of GB-29 Total tablets by our Company and allegedly dealing in fixed-dose combination drugs without having the requisite permission from Drug Controller General. The Directors named in the Complaint and the erstwhile company secretary of our Company filed a criminal miscellaneous application dated August 31, 2023, before the High Court of Judicature at Patna (" Patna High Court ") for quashing the proceedings arising from the Complaint under section 482 of the Code of Criminal procedure, 1973.	Drug Inspector, Muzaffarpur, Drugs Control Administration	Pursuant to an order dated August 8, 2024, the Patna High Court stayed the proceedings arising from the Complaint till the pendency of the matter before the Patna High Court. The matter is currently pending.	-
6.	The Union of India, through Drug Inspector, Central Drugs Standard Control Organisation, Sub-Zone Jammu, filed a complaint dated July 26, 2018 (" Complaint ") before the court of the Chief Judicial Magistrate, Jammu, against our Company, certain of our Directors, namely Ankur Kirtikumar Mehta, Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta and Viral Bhupendrabhai Sitwala, our Shareholders Brinda Mehta and Meena Mehta, and certain others, under Sections 18(a)(i) and 27(d) of the Drugs and Cosmetics Act, 1940, as amended, (" Drugs and Cosmetics Act ") for allegedly manufacturing, selling and distributing Desogestrel & Ethinylestradiol (Locipil tablets) which were not of standard quality under section 18(a) read with section 16 punishable under section 27(d) of the Drugs and Cosmetics Act.	Drug Inspector, Central Drugs Standard Control Organisation, Sub-Zone Jammu	Ankur Kirtikumar Mehta, Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta filed a criminal miscellaneous petition dated May 1, 2019, before the High Court of Jammu and Kashmir for quashing the proceedings arising from the Complaint and an order dated July 26, 2018, passed by the Chief Judicial Magistrate, Jammu, issuing process and summons against them under section 561(A) of the Code of Criminal procedure, 1973. The matter is currently pending.	-

C. Disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any: Nil.

D. Brief details of outstanding criminal proceedings against the Promoters: Nil.

ANY OTHER IMPORTANT INFORMATION AS PER BOOK RUNNING LEAD MANAGERS/COMPANY - NIL

DECLARATION BY OUR COMPANY

We hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, or the rules, regulations or guidelines issued by the Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with, and no statement made in this Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contract (Regulation) Rules, 1957 and the Securities and Exchange Board of India Act, 1992, each as amended, or the rules, regulations or guidelines issued thereunder, as the case may be. We further certify that all the disclosures and statements made in the Red Herring Prospectus are true and correct.

DECLARATION BY THE SELLING SHAREHOLDERS

Each of the Selling Shareholders, hereby confirm that all statements, disclosures and undertakings specifically made or confirmed by us in the Red Herring Prospectus in relation to ourselves, as a Selling Shareholder and our portion of the Offered Shares, are true and correct. We assume no responsibility for any other statements, disclosures and undertakings, including, any of the statements, disclosures and undertakings made or confirmed by or relating to the Company or any other Selling Shareholder(s) or any other person(s) in the Red Herring Prospectus.

TIMING FOR SUBMISSION OF BID CUM APPLICATION FORMS/REVISIONS FORMS

Bids and any revision in Bids shall be accepted only between 10.00 a.m. and 5.00 p.m. (Indian Standard Time) during the Bid/ Issue Period (except the Bid/ Issue Closing Date) at the bidding centres mentioned in the Bid cum Application Forms, to the SCSBs at the Designated SCSB Branches (a list of such branches is available at the website of the SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35>) or with Designated Intermediaries. On the Bid/ Issue Closing Date, the Bids and any revision in the Bids shall be accepted only between 10.00 a.m. and 5.00 p.m. IST.

DETAILS OF BIDDING CENTRES

JM FINANCIAL SERVICES LIMITED

AHMEDABAD: Mr.Chetan Pandit/Mr. Yatin shah JM Financial Services Ltd, G-10 Chinubhai Centre, Gr. Flr, Nehru Bridge Corner, Ashram Road, Ahmedabad 380 009 Ph: 079-2657 6666 - 70/30013700 M.Kathir Eureka Stock & Share Broking Services Ltd, Block - B, 405/A, Shivalic Corporate Park, Behind IOC Petrol Pump, Near Shivrangani Cross Road, Satellite, Ahmedabad – 380015 Ph: (079) 26925572 & 48917258 (Mobile No.9099401802) Mitesh Patel Tradebulls Securities (P) Ltd, 232, The Sunrise Mall, Nr. Swaminarayan Temple, Bodakdev, Ahmedabad: 380052 Ph: 079-40001071 .M-9898183600 SMC Global, 10-A, Kalapurnam, C G Road, Near Municipal Market, Ahmedabad 380003 Ph no 9825612323, 09727799200 Pravin Ratilal Sharedalal, Sarkar-1, 5th Floor, Opp. Ganghigram Railway Station, Navrangpura, Ahmedabad-380009 Ph: 26553700/. Ajay Patel Anand Rathi, 201-301, Earth Arise, 3rd Floor, Nr. YMCA Club, S G Highway, Makarba, Ahmedabad - 380 015. India Ph: 9574007637; **MUMBAI:** Mr. Sona Verghese/ Tejas Agrawal/Ms Armin Irani JM Financial Services Ltd, 2, 3, 4 Kamanwala Chambers, Ground Floor, Sir P M Road, Fort, Mumbai 400 001 Ph: 022-2266 5577 - 80, 6136 3400 Mr Ashit Vora/Mr. Praveen Manchekar JM Financial Services Ltd, 502, 5th Floor, Kingston, Tejpal Road, Near Railway Crossing, Vile Parle (East), Mumbai 400 057 Ph: 022-26636731-34, 26135202-03 Ms Jyotsna Solanki/Mr. Bipin Chauhan JM Financial Services Ltd, 1st Floor, 101, 1st Floor, Abhilasha II CHSL, Punjabi Lane, Off Chandavarkar Road, Borivali West, Mumbai -400092. Ph: 22 29686703 | 22 29686700 Mr. Sunil Gujar JM Financial Services Ltd, 328, 3 rd Floor, Vardhman Market, Sector 17, Above DCB, Vashi, Navi Mumbai Ph: 6632 9200/03/ 04/ 27896024-26 Mr. Swapnil JM Financial Services Ltd, Atlantic Commercial Tower, 211, 2nd Floor, RB Mehta Marg, Near Patel Chowk & Jain Mandir, Ghatkopar (East), Mumbai – 400 077 Ph: 022 – 25013607 Mr. Nayan Parikh/Ms. Jyoti Sharma JM Financial Services Ltd, Abhishek Commercial Complex, Office No.8, 1st Floor, Above Dena Bank, Next to Aditi Hotel, Plot No.104, S V Road, Malad West, Mumbai-400064 Ph: 022- 288 22 831 / 32 /34 Ms. Prajakta Bhawe JM Financial Services, Corner Stone, 2nd Floor, Office No.209, Plot No. CTS N0-75/B, Tika Nagar 18, Hari Niwas Circle, Thane West-400602. Sachin M Tamhankar/ Shrikant Sathe Almondz Global Securities, C/o.9, Crescent Chambers, 2nd Floor, 56, Tamirand Lane, Fort, Mumbai-400001 Ph: 022-22618137 Mr. Rajesh Tadani Centrum Broking Ltd, Centrum House, CST Road, Vidyanagri Marg, Kalina, Santacruz East, Mumbai-400098 Ph: 42159000 Dinesh Waghela Dinesh Waghela, LKP Securities, 207, Veena Chambers, 21 Dalal Street, Fort, Mumbai-400001.Ph: 022-22660171 Ph: 022-22660171 Mr. Prakash Boricha/Mr. Madhuri Tawde Nuvama Wealth and Investment Limited (Edelweiss Broking Limited), 104, P J towers, BSE Bldg, Fort, Mumbai -01 Ph: 022-67494580 Kamal Padia Eureka Stock & Share Broking Services Ltd, Raheja Chambers, R.No.909, 9th Floor, Nariman Point Mumbai - 400 021 Ph: (022) 3258 3020 HDFC Securities Limited, I Think Techno Campus Building-B, “Alpha”, Office Floor 8, Opp. Crompton Greaves, Near Kanjurmarg Station Kanjurmarg(East), Mumbai 400 042 India Ph: 022-30753440 Mitesh Shah/Vivek Anerao/Mr. Rajat Rawal ICICI Securities Limited, ICICI Venture House, 2nd Floor, Institution Operations, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400025, Ph: 022-6807 7463 Abhijit Prabhu IDBI Capital Markets & Securities, 5th Floor, IDBI Tower, Cuffe Parade, Colaba, Mumbai-400005 Ph: 9619817448/022-22171946 Santosh Patil/Nitin Sarkar Motilal Oswal Securities, Motilal Oswal Tower, Gokhale Sayani Road, Prabhadevi, Mumbai: - 400 025 Ph: 9167916945 Archana Dedhia SBICAP Securities, Marathon Future, A&B Wing, 2nd Floor, Lower Parel Mumbai-400013Ph: 022-42273446 Yatish Sharekhan Ltd, 10th Floor, Beta building, Lodha iThink Techno Campus, Off; JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (E), Mumbai-400042 Ph: 022-67502000 SMC Global, 258, Perin Nariman Street First Floor Fort Mumbai -400001 Ph no 9930055430 Asit C Mehta Investment Intermediated Ltd, 67, Poddar Chambers, S A Brelvi Road, Fort, Mumbai-400001 Ph: 61325959 Mitesh Shah/Vivek Anerao/Mr. Rajat Rawal ICICI Securities Limited, ICICI Venture House, 2nd Floor, Institution Operations, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400025, Ph: 022-6807 7463 Mr. Shrikrishna Haryan YES Securities (India) Limited, AFL House, 4th Floor, Lok Bharati Complex, Marol-Maroshi Road, Andheri (E), Mumbai -400059 Tel: +91 (22) 3347 7017 |Mob: (+91) 95940 83673 Mr. Nilesh Shinde Prabhudas Lilladher Pvt Ltd, Sadhana House, 3 rd Floor, 570, P. B. Marg, Behind Mahindra Tower, Worli, Mumbai-400018 Tel: 022-66322222/91 Shekhar Margaje Anand Rathi, A - Wing, 901, 9th Floor, Express Zone, Western Express Highway, Opp. Oberoi Mall, Malad(East), Mumbai - 400 097 Ph: 9869323656 Sunil Singh Anand Rathi, Shop no. 5, Arihant Darshan, 90 Feet Road, Next to IDBI BANK. Bhayandar (W) – 401101 Ph: 9867934960 . Avinash Singh Anand Rathi, Shop No. 10, Grd Flr, Chandan Mansion, Opp. Portuguese Church, Gokhale Road, Dadar (W), Mumbai – 400028 Ph: 9819918988 Nilesh Pandya Anand Rathi, Grd Flr, Shop No. 3&4, Raghukul Bldg, Tata Lane, Near Kasturi Plaza, Ramnagar, Dombivali (E) Ph: 9892313432 Ballabh Kothari Anand Rathi, Shop No. 55, Grd Flr, Bhatia Niwas, Bhuleshwar, 466, Chira Bazar, J.S.S Road, Mumbai 400002 Ph: 9324843611 DEEPAK K VYAS Anand Rathi, SHOP 11 GROUND FLR, THACKER TOWER, PLOT 86, SECTOR 17, VASHI, NAVI MUMBAI-400703 Ph: 9833489090 Mahajan KJMC Capital Market Services, 168, 16Th Floor, Atlanta, 209, Nariman Point, Mumbai-400021 Ph: 22885201 **NEW DELHI:** Mr. Umesh Yadav/Mr. Ashishkumar Jhigran JM Financial Services Ltd, 5 G&H, 5th Floor, Hansalaya Building, 15, Barakhamba Road, New Delhi -110 001 Phone (011) 49537800 Manoj Arora/Manish Chopra Almondz Global Securities, 2nd Floor, 3-Scindia House, Janepath, New Delhi-110001 Ph: 011-41514666-69 Religare Securities Ltd, 2nd Floor, Rajlok Building, 24, Nehru Place, New Delhi Ph: 11 46272400 Religare Securities Ltd, Ground Floor, Property No. 1, DLF Industrial Area, Moti Nagar, New Delhi Ph: 918800191497 Jeethesh Kumar RR Equity Brokers, 47, M M Road, Rani-Jhansi

DETAILS OF BIDDING CENTRES

Marg, Jhandewalan, New Delhi-110055 Ph: 011-22636362-63 SMC Global, 17, Netaji Subhash Marg, Daryaganj, New Delhi-110 002 Ph no 9910644949, 8595851823 Jyoti Dodeja Anand Rath, 2nd Floor, Unit No. 6, DDA Building No. 11, Vardhman Trade Centre, Nehru Place, New Delhi- 110 019 Ph: 9313133170/81301 07700 Mr. Puneet Gupta Globe Capital Markets, 609, Ansal Building, 16 KG Marg, Connaught Place, New Delhi 110001 Axis Capital Ltd, 2nd Floor, Level 3B (4th Floor), DLF Centre, Sansad Marg, Connaught Place, New Delhi, Pin: 110001, Ph: 011 – 61289088

IIFL CAPITAL SERVICES LIMITED (Formerly known as IIFL Securities Limited)

AHMEDABAD: IIFL Capital, 801-802 8th FLOOR, ATHENS BY A.SHRIDHAR,SHIVARANJNI CROSS ROAD,SATELLITE AHMEDABAD-380015 Phn No: 9825063699; **IIFL Capital**, 801-802 8th FLOOR ,ATHENS BY A.SHRIDHAR,SHIVARANJNI CROSS ROAD,SATELLITE AHMEDABAD-380015 Phn No: 8657405993/ 9712916547; **RR Equity**, 401, Abhijit-1, Opp. Bhuj Mercantile Bank, Mithakhali, 6 Road, Navrangpura, Ahmedabad-390009 Phn No: 9898924399; **SMC Global Securities Ltd**, 10-A, Kalapurnam,C G Road ,Near Municipal Market, Ahmedabad 380003 Ph no 9825612323, 09727799200 , Phn No: 9727799232 ; **DELHI: IIFL Capital**, 510-514,5th Floor,Ashoka Estate Bldg - 24, Barakhamba Road,Connaught Place Phn No: 011-45259055 /9871047900; **RR Equity**, 412-422, Indraprakash Building, 21, Barakhamba Road, New Delhi – 110001 Phn No: 7307331523 ; **SMC Global Securities Ltd**, 17 , Netaji Subhash Marg, Daryaganj, New Delhi-110 002 Ph no 9910644949, 9810059041, Phn No: 8595851823 ; **Axis Capital Limited.**, Alt-F Coworking, 5th Floor Stateman House, Barakhamba Road, New Delhi – 110001. Tel: 9811030626; **MUMBAI: IIFL Capital**, 1A/105, Building No 105,Opp. Bharat House, Mumbai Samachar Marg, Fort Mumbai Phn No: 9167997482 /9167997481 / 022-49142114/123; **IIFL Capital**, 201, 2nd Flr,Cabin No:5, Parasmani Shopping Centre,Parasmani Complex,Nr Dadar Rlwy Stn, 95 Naigaum Cross Rd,MMGS Marg, Dadar Phn No: 022-48843147 /9321592975; **IIFL Capital**, 6th Floor, Akruti Centre Point, Central Road,Marol MIDC, Andheri East, Mumbai Phn No: 9004930729 / 022-62728874; **IIFL Capital Ltd**. 311-Jalaram business Center 3rd flr Ganjawalla Lane chamunda circle Above Axis Bank Borivali west, Mumbai 400 092 Phn No: 9850207105/9967816301; **IIFL Capital Ltd** ,Ground Floor,Huibtown Solaris,N. S. Phadke Marg, Vijay Nagar,Opp Teli Galli, Andheri (East),Mumbai 400 069 Phn No: 9820188714; **IIFL Capital Ltd** , Shop No 2, Ground Floor, Surya Darshan Apt,Pai Nagar, Near Ganjawala Petrol Pump,Borivali West, Mumbai – 400092, Phn – 9619234694 **ICICI Securities Limited**, ICICI Venture House, Appsahab Marathe Marg, Prabhadevi, Mumbai – 400 025, Phn No: 9819621186; **SBICap Securities**, Marathon Futorex, Unit 1201, B Wing, 12th Floor, N.M. Joshi Marg, Mafatlal Mill Compound, Lower Parel (East), Mumbai – 400013, Phn No: 022 69316400; **LKP Securities**, 207, VEENA CHAMBERS, 21, DALAL STREET, FORT, MUMBAI 400 001, Phn No: 22660171 / 9821067167; **RR Equity**, 82/1, Apollo House, Ground Floor, Opposite Jammu & Kashmir Bank, Mumbai Samachar Marg, Mumbai 400023, MAHARASHTRA Phn No: 9324804090 ; **SMC Global Securities Ltd**, 258,Perin Nariman Street First Floor Fort mumbai -400001 Ph no 9930055430 , Phn No: 9930055430 ; **Share Khan Limited**, Gigaplex Building No. 09, 10th Floor,Raheja Mindspace 2, Airoli Knowledge Park,Airoli – Navi Mumbai 400708, Ph.No 9870267725; **Yes Securities Limited**, AFL House, 4th Floor, Lok Bharati Complex, Marol-Maroshi Road, Andheri East, Mumbai – 400 059, Phn No: 9920268651; **HDFC Securities**, I Think Techno Campus, Building, B, Alpha, Office Floor 8, Near Kanjurmarg Station, Kanjurmarg (East), Mumbai -400 042, Ph No. 022 3074 3400; **Motilal Oswal Financial Services Limited**, 6th Floor,602,Interface 11,Mind Space New Link Road, Malad West Mumbai 400064 Phone: 9167916945

KOTAK SECURITIES LIMITED

AHMEDABAD: Kotak Securities Limited., 16th Floor | SHAPATH – V | Opp. Karnavati Club | Sarkhej-Gandhinagar Highway | Ahmedabad – 380015; Anand Rath Share & Stock Brokers Ltd., A-805 Mondeal Heights Nr Novotel Hotel Ramdev Nagar SG Highway Ahmedabad; IDBI Capital Markets & Securities Ltd., 3rd Chandan house opp abhijit -3, near mithakali circle, T: (+079) 40075054 / 55 / 56 / 9374523201; Pravin Ratilal Share And Stock Brokers Limited., “Sakar-I”, 5th Floor, Opp. Gandhigram Railway Station, Navrangpura.Tel: 079-66302700RR Equity Brokers Private Limited., 401, Abhijit-1, Opp. Bhuj Mercantile Bank, Mithakhali, 6 Road, Navrangpura, P:40211888, 9327037108; SMC Global Sec Ltd., 10-A, Kalapurnam,C G Road ,Near Municipal Market, Ahmedabad 380003 Ph no 9825612323, 09727799200 **MUMBAI: Kotak Securities Limited., 32, Gr Flr., Raja Bahadur Compound, Opp Bank of Maharashtra, Fort, T: 22655084**; Centrum Broking Ltd., “Centrum House” 3rd Level, Vidyanagari Marg, Kalina, Santacruz (East), Nuvama Wealth and Investment Limited (Edelweiss Broking Limited),, 104, P J towers, BSE Bldg, Fort, Mumbai -01. Tel: 022-67494580; Motilal Oswal Securities Limited., Motilal Oswal Towers,Junction of Gokhale & Sayani Road, Prabhadevi, T: 022-62786726/6722Prabhudas Lilladher Pvt Limited., Sadhana House, 3rd Floor, 570 P.B.Marg, Behind-Mahindra Towers, Worli, Tel:022-66322222/91; SBICap Securities Ltd., Marathon Futorex, B Wing, 12th Floor, Mafatlal Mill Compound N M Joshi Marg, Lower Parel (E), M: 9004171434; Sharekhan Ltd., Gigaplex Building No. 09, 10th Floor,Raheja Mindspace 2, Airoli Knowledge Park,Airoli – Navi Mumbai 400708. T: 9870267725; YES Securities (India) Limited., AFL House, 4th Floor, Lok Bharati Complex, Marol-Maroshi Road, Andheri (E), Mumbai -400059; **NEW DELHI: Kotak Securities Limited., Unit number 601 & 608, 6th Floor, World Trade Tower Building, Tower B, Plot number C1, Sector 16, Noida, (New Delhi) - 201301.Tel: 0120-6760435/0120-4869326**; Anand Rath Share & Stock Brokers Ltd., 2nd Floor, Unit No. 6, DDA Building No. 11, Vardhman Trade Centre, Nehru Place, T: 9313133170/81301 07700; Axis Cap. Ltd., Alt-F Coworking, 5th Floor Statesman House, Barakhamba Road, New Delhi – 110001. Tel: 9811030626 / 9312037774; IDBI Capital Markets & Securities Ltd., Office No. 207-208, Second Floor, Sagar Plaza, Plot No.19, District Centre Laxmi Nagar, Delhi-110092; RR Equity Brokers Private Limited., 412-422, Indraprakash Building 21,Barakhamba Road, T: 23354802; SMC Global Securities Limited., 17, Netaji Subhash Marg, Darya Ganj.

THIS SPACE IS INTENTIONALLY LEFT BLANK

THIS SPACE IS INTENTIONALLY LEFT BLANK

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID REVISION FORM

I/We (on behalf of joint Bidders, if any) confirm that the Acknowledgement Slip for my/our Bids is enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in the Bid Cum Application Form submitted earlier by me/us. I/We (on behalf of joint Bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my/our existing Bids as appearing on the electronic book building system do not tally with the details given in this Bid Revision Form.

INSTRUCTIONS FOR FILLING UP THE REVISION FORM

- Name of Sole Bidder / First Bidder should be exactly the same as it appears in the depository records. In case of joint Bids, the Bid cum Application Form should contain only the name of the First Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The Bid means an "indication to make an offer" and not "an offer".
- Please ensure that the Bid options provided are in the same order as that provided in the Bid cum Application Form submitted earlier.
- In case there is no change in the particular Bid option, please write "NO CHANGE". In case you want to cancel the Bid option, please write "CANCELLED".
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total Bid Amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your bank has notified an SCSB Branch in the city where the Bid cum Application Form is being submitted.
- Revision of Bids in case of Revision of Price Band:** In case of an upward revision in the Price Band, Retail Individual Bidders who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount plus additional payment does not exceed ₹ 0.2 million if the Bidder wants to continue to Bid at Cut-off Price), with the SCSBs/ members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds ₹ 0.2 million, the Bid will be considered for allocation under the Non-Institutional Portion in terms of the RHP or the Preliminary Offering Memorandum as applicable. If, however, the Bidder does not either revise the Bid or make additional payment and the Offer Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. In case of a downward revision in the Price Band, announced above, Retail Individual Bidders who have bid at Cut-off Price, could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
- Only the Sole Bidder / First Bidder is required to sign the Bid cum Application Form / Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of sole Bidder and ASBA bank account or UPI ID linked with the bank account of First Bidder in case of joint Bidder, in the application form. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c are liable to be rejected.
 - QIB cannot apply through UPI mechanism and Non-Institutional Investors bidding for an amount exceeding ₹ 0.5 million cannot use UPI Mechanism to apply. UPI Bidders applying up to ₹ 0.5 million can apply through UPI mode as per NPCI vide circular reference no. NPCI/UPI/OC No. 127/2021-22 dated December 9, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
 - For Retail Individual Bidders (RIBs) and Individuals applying as Non-Institutional Bidders with Application size up to ₹ 0.5 million ("UPI Bidders") bidding through the UPI Mechanism.**
 - Please ensure that your bank is offering UPI facility for public offers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the (a) bank where the bank account linked to their UPI ID is maintained; and (b) UPI Bidders bidding through the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
 - UPI Bidders bidding through the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on 415 of the RHP.
- Other Instructions:** a. Revision to Bids must be made only in the prescribed Revision Form, as applicable; b. Revision Form must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the members of the Syndicate/ SCSBs/Registered Brokers/RTA/CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Forms; c. Ensure that Acknowledgement Slip for your Bid and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to issue instruction to block the revised amount in excess of their original blocked amount based on the cap of the revised Price Band upon an upward revision of their Bid.
- Revisions (i) in the Bid, the Bidders/Applicants will have to use the services of the same Designated Intermediary through which such Bidder/Applicant had placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Revision Form and the Bid(s) must be made only in such Revision Form or copies thereof. Investors must ensure that their PAN is linked with Aadhaar card and are in compliance with the Central Board of Direct Taxes notification dated February 13, 2020 and press release dated June 25, 2021 read with press release dated September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022, read with press release dated March 28, 2023 and any subsequent press releases in this regard.

OFFER STRUCTURE

Particulars	Eligible Employees ¹	QIBs ⁽¹⁾	NIs	RIs
Number of Equity Shares available for Allotment or allocation ⁽²⁾	Up to (a) Equity Shares of face value of ₹10 each	Not more than (a) Equity Shares of face value of ₹10 each, aggregating to ₹ (a) million, subject to the allocation/ allotment of not more than 50% of the Net Offer	Not less than (a) Equity Shares of face value of ₹10 each, available for allocation or Net Offer less allocation to QIB Bidders and RIs	Not less than (a) Equity Shares of face value of ₹10 each, available for allocation or Net Offer less allocation to QIB Bidders and Non-Institutional Investors
Percentage of Offer Size available for Allotment or allocation	The Employee Reservation Portion shall constitute up to (a) % of the post-Offer paid-up equity share capital of our Company	Not more than 50% of the Net Offer being available for allocation to QIB Bidders. However, up to 5% of the QIB Portion will be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining QIB Portion (excluding the Anchor Investor Portion). The unsubscribed portion in the Mutual Fund Portion will be available for allocation to other QIBs	Not less than 15% of the Net Offer less allocation to QIB Bidders and RIs shall be available for allocation, subject to the following: (i) one-third of the portion available to NIs shall be reserved for applicants with an application size of more than ₹ 0.20 million and up to ₹ 1.00 million; and (ii) two-third of the portion available to NIs shall be reserved for applicants with application size of more than ₹ 1.00 million. Provided that the unsubscribed portion in either of the subcategories specified above may be allocated to applicants in the other sub-category of NIs	Not less than 35% of the Net Offer or the Offer less allocation to QIB Bidders and Non-Institutional Investors will be available for allocation
Basis of Allotment if respective category is oversubscribed	Proportionate; unless the Employee Reservation Portion is undersubscribed, the value of allocation to an Eligible Employee shall not exceed ₹0.20 million (net of Employee Discount, if any). In the event of undersubscription in the Employee Reservation Portion, the unsubscribed portion may be allocated, on a proportionate basis, to Eligible Employees Bidding in the Employee Reservation Portion for value exceeding ₹0.20 million (net of Employee Discount, if any), subject to total Allotment to an Eligible Employee not exceeding ₹0.50 million (net of Employee Discount, if any)	Proportionate as follows (excluding the Anchor Investor Portion): a) Up to (a) Equity Shares of face value of ₹10 each, shall be available for allocation on a proportionate basis to Mutual Funds only; b) Up to (b) Equity Shares of face value of ₹10 each, shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above; and up to (c) Equity Shares of face value of ₹10 each, may be allocated on a discretionary basis to Anchor Investors. 40% of the Anchor Investor Portion shall be available for allocation as follows, (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in (ii) above, the allocation may be made to domestic Mutual Funds.	The Allotment of Equity Shares to each NI shall not be less than the minimum application size, subject to availability in the Non-Institutional Portion, and the remainder, if any, shall be allotted on a proportionate basis in accordance with the conditions specified in Schedule XIII to the SEBI ICDR Regulations	The allotment to each RI shall not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining available Equity Shares (if any, shall be Allotted on a proportionate basis. See "Offer Procedure" beginning on page 415.
Mode of Bid**	Through ASBA process only (including the UPI Mechanism)	Through ASBA process only (except Anchor Investors) (excluding the UPI Mechanism)	Through ASBA process only (including the UPI Mechanism for Bids up to ₹ 0.50 million)	Through ASBA process only (including the UPI Mechanism)
Minimum Bid	(a) Equity Shares of face value of ₹10 each	Such number of Equity Shares in multiples of (a) Equity Shares of face value of ₹10 each, such that the Bid Amount exceeds ₹ 0.20 million.	For Non-Institutional Investors applying under one-third of the Non-Institutional Portion (with application size of more than ₹ 0.20 million and up to ₹ 1.00 million) such number of Equity Shares in multiples of (a) Equity Shares of face value of ₹10 each, such that the Bid Amount exceeds ₹ 0.20 million. For Non-Institutional Investors applying under two-thirds of the Non-Institutional Portion (with application size of more than ₹ 1.00 million) such number of Equity Shares in multiples of (a) Equity Shares of face value of ₹10 each, such that the Bid Amount exceeds ₹ 1.00 million.	(a) Equity Shares of face value of ₹10 each
Maximum Bid	Such number of Equity Shares in multiples of (a) Equity Shares of face value of ₹10 each, so as to ensure that the Bid Amount by each Eligible Employee does not exceed ₹ 0.50 million less Employee Discount, if any	Such number of Equity Shares in multiples of (a) Equity Shares of face value of ₹10 each, not exceeding the size of the Net Offer (excluding the Anchor Investor Portion), subject to applicable limits to each Bidder	For Non-Institutional Investors applying under one-third of the Non-Institutional Portion (with application size of more than ₹ 0.20 million and up to ₹ 1.00 million) such number of Equity Shares in multiples of (a) Equity Shares of face value of ₹10 each, such that the Bid Amount does not exceed ₹ 1.00 million. For Non-Institutional Investors applying under two-thirds of the Non-Institutional Portion (with application size of more than ₹ 1.00 million) such number of Equity Shares in multiples of (a) Equity Shares of face value of ₹10 each, such that the Bid Amount does not exceed ₹ 1.00 million.	Such number of Equity Shares in multiples of (a) Equity Shares of face value of ₹10 each, such that the Bid Amount does not exceed ₹ 0.20 million
Mode of Allotment	Compulsorily in dematerialised form			
Bid Lot	(a) Equity Shares of face value of ₹10 each and in multiples of (a) Equity Shares thereafter			
Allotment Lot	(a) Equity Shares of face value of ₹10 each and in multiples of (a) Equity Shares thereafter	(a) Equity Shares of face value of ₹10 each, and in multiples of one Equity Share of face value of ₹ 10 each thereafter	For NIs allotment shall not be less than the Minimum Non-Institutional Application Size.	(a) Equity Shares of face value of ₹10 each, and in multiples of one Equity Share of face value of ₹ 10 each thereafter
Trading Lot	One Equity Share	Public financial institutions as specified in Section 2(72) of the Companies Act, scheduled commercial banks, multilateral and bilateral development financial institutions, Mutual Funds, FPIs other than individuals, corporate bodies and family offices, VCFs, AIFs, FVCI, state industrial development corporation, insurance company registered with IRDAI, provident funds with minimum corpus of ₹ 250.00 million, pension funds with minimum corpus of ₹ 250.00 million registered with the Pension Fund Regulatory and Development Authority established under the provisions of Pension Fund Regulatory and Development Authority Act, 2013, National Investment Fund set up by the GoI, insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India, Systemically Important NBFCs, and accredited investors as defined in regulation 2(1)(ab) of the SEBI AIF Regulations, for the limited purpose of their investment in Angel Funds (as defined in SEBI AIF Regulations) registered with SEBI, under the SEBI AIF Regulations, in accordance with applicable laws.	Resident Indian individuals, Eligible NRIs, HUFs (in the name of the Karta), companies, corporate bodies, scientific institutions, societies, and trusts and any individuals, corporate bodies and family offices which are re-categorised as category II FPI (as defined in the SEBI FPI Regulations) and registered with SEBI.	Resident Indian individuals, Eligible NRIs and HUFs (in the name of the Karta)
Who can apply ⁽³⁾	Eligible Employees			
Term of Payment	In case of Anchor Investors: Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids In case of all other Bidders: Full Bid Amount shall be blocked by the SCSBs in the bank account of the Bidders, or by the Sponsor Bank(s) through the UPI Mechanism (other than Anchor Investors) that is specified in the Bid cum Application Form at the time of the submission of the Bid cum Application Form			

¹ Assuming full subscription in the Offer.

² Anchor Investors are not permitted to use the ASBA process. Further, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/2022/75 dated May 30, 2022, had mandated that ASBA applications in public issues shall be processed only after the application monies are blocked in the investor's bank accounts. Accordingly, Stock Exchanges shall, for all categories of investors and also for all modes through which the applications are processed, accept the ASBA applications in their electronic book building platform only with a mandatory confirmation on the application monies blocked.

³ Eligible Employees Bidding in the Employee Reservation Portion can Bid up to a Bid Amount of ₹ 0.50 million (net of Employee Discount, if any). However, a Bid by an Eligible Employee in the Employee Reservation Portion will be considered for allocation, in the first instance, for a Bid Amount of up to ₹ 0.20 million (net of Employee Discount, if any). In the event of under-subscription in the Employee Reservation Portion, the unsubscribed portion will be available for allocation and Allotment, proportionately to all Eligible Employees who have bid in excess of ₹ 0.20 million (net of Employee Discount, if any), subject to the maximum value of Allotment made to such Eligible Employee not exceeding ₹ 0.50 million (net of Employee Discount, if any). An Eligible Employee Bidding in the Employee Reservation Portion (subject to Bid Amount being up to ₹ 0.20 million) can also Bid in the Retail Portion, and such Bids shall not be considered Multiple Bids. The unsubscribed portion if any, in the Employee Reservation Portion shall be, added to the Net Offer. In case of under-subscription in the Net Offer, spill-over to the extent of such under-subscription shall be permitted from the Employee Reservation Portion.

SEBI vide the SEBI ICDR Master Circular, has mandated that ASBA applications in public issues shall be processed only after the application monies are blocked in the bank accounts of the investors. Accordingly, Stock Exchanges shall, for all categories of investors viz. QIBs, NIs and RIs and also for all modes through which the applications are processed, accept the ASBA applications in their electronic book building platform only with a mandatory confirmation on the application monies blocked.

⁴ Our Company may, in consultation with the BRLMs, allocate up to 60% of the QIB Portion to Anchor Investors at the Anchor Investor Offer Price, on a discretionary basis, subject to there being (i) a minimum of two and maximum of 15 Anchor Investors, where allocation in the Anchor Investor Portion is up to ₹ 2,500 million, subject to a minimum allotment of ₹ 50 million per Anchor Investor, and (ii) a minimum of five and maximum of 15 Anchor Investors, where the allocation under the Anchor Investor Portion is more than ₹ 2,500 million, but up to ₹ 2,500 million and an additional 15 Anchor Investors for every additional ₹ 2,500 million or part thereof, will be permitted, subject to a minimum Allotment of ₹ 50 million per Anchor Investor. An Anchor Investor will make a minimum Bid of each number of Equity Shares, that the Bid Amount is at least ₹ 100 million. 40% shall be available for allocation as follows, (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in (ii) above, the allocation may be made to domestic Mutual Funds. For details, see "Offer Procedure" on page 415.

⁵ Subject to valid Bids being received at or above the Offer Price. This Offer is being made in accordance with Rule 19(2)(b) of the SCRR and Regulation 6(1) of the SEBI ICDR Regulations.

⁶ In the event that a Bid is submitted in joint names, the relevant Bidders should ensure that the depository account is also held in the same joint names and the names are in the same sequence in which they appear in the Bid cum Application Form. The Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such first Bidder would be required in the Bid cum Application Form and such first Bidder would be deemed to have signed on behalf of the joint holders.

⁷ Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Forms provided that any difference between the Anchor Investor Allocation Price and the Anchor Investor Offer Price shall be payable by the Anchor Investor pay-in-date as indicated in the Confirmation of Allotment Note ("CAN").

⁸ Bids by FPIs with certain structures as described under "Offer Procedure - Bids by Foreign Portfolio Investors" beginning on page 422 and having the same PAN may be collated and identified as a single Bid in the Bidding process. The Equity Shares Allotted and Allotted to such successful Bidders (with the same PAN) may be proportionately distributed.

⁹ Bidders will be required to confirm and will be deemed to have represented to our Company, each of the Selling Shareholders, the Underwriters, their respective directors, officers, designated partners, partners, trustees, associates, agents, affiliates and representatives that they are eligible under applicable law, rules, regulations, guidelines and approvals to acquire the Equity Shares.

**COMMON BID
REVISION FORM**



To,
The Board of Directors
CORONA REMEDIES LIMITED

CORONA REMEDIES LIMITED - INITIAL PUBLIC OFFER - NR

Corporate Identity Number: U24231GJ2004PLC044656
Registered and Corporate Office: CORONA House, C- Mondeal Business Park, Near Gurudwara, S. G. Highway, Thaltej, Ahmedabad 380 059,
Gujarat, India; Contact Person: Chetna Prabhakar Dharajiya, Company Secretary and Compliance Officer; Telephone: +91 79 4023 3000;
E-mail: complianceofficer@coronaremedies.com; Website: www.coronaremedies.com

FOR NON-RESIDENTS, INCLUDING ELIGIBLE
NRIs, FPIs, FVCIs AND REGISTERED MULTI
LATERAL AND BILATERAL DEVELOPMENT
FINANCIAL INSTITUTIONS ETC. APPLYING ON A
REPATRIATION BASIS.

100% BOOK BUILT OFFER
ISIN: INE02ZQ01018
LEI No.: 894500F0QWX23PSWWE23

**Bid cum
Application
Form No.**

MEMBERS OF THE SYNDICATE'S STAMP & CODE	SUB-SYNDICATE MEMBER'S/ REGISTERED BROKER'S SCSB'S/CDP'S/RTA'S STAMP & CODE	1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER Mr. /Ms./M/s. _____ Address _____ _____ Email _____ Tel. No. (with STD code) / Mobile _____
SUB-BROKER'S / SUB-AGENT'S STAMP & CODE	SCSB BRANCH STAMP & CODE	2. PAN OF SOLE / FIRST BIDDER _____
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.	3. BIDDER'S DEPOSITORY ACCOUNT DETAILS <input type="checkbox"/> NSDL <input type="checkbox"/> CDSL For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID

PLEASE CHANGE MY BID

4. FROM (AS PER LAST BID OR REVISION)										Price per Equity Share (₹)/ "Cut-off" (Price in multiples of ₹1/- only)									
Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised)									(In Figures Only)									
	(In Figures)									Bid Price			Retail Discount			Net Price			"Cut-off" (Please ✓ tick)
	8	7	6	5	4	3	2	1	3	2	1	3	2	1	3	2	1		
Option 1																			
(OR) Option 2																			
(OR) Option 3																			

5. TO (REVISED BID) (ONLY RETAIL INDIVIDUAL BIDDERS CAN BID AT "CUT-OFF")										Price per Equity Share (₹)/ "Cut-off" (Price in multiples of ₹1/- only)									
Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised)									(In Figures Only)									
	(In Figures)									Bid Price			Retail Discount			Net Price			"Cut-off" (Please ✓ tick)
	8	7	6	5	4	3	2	1	3	2	1	3	2	1	3	2	1		
Option 1																			
(OR) Option 2																			
(OR) Option 3																			

6. PAYMENT DETAILS [IN CAPITAL LETTERS]										PAYMENT OPTION : FULL PAYMENT <input checked="" type="checkbox"/>									
Additional Amount Blocked (₹ in figures) _____ (₹ in words) _____																			
ASBA Bank A/c No. _____ Bank Name & Branch _____ OR UPI ID (Maximum 45 characters) _____																			

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS BID REVISION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC OFFERS ("GID") AND HEREBY AGREE AND CONFIRM THE "BIDDER'S UNDERTAKING" AS GIVEN ALONG WITH THIS BID CUM APPLICATION FORM. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THIS BID REVISION FORM GIVEN OVERLEAF.

7A. SIGNATURE OF SOLE/ FIRST BIDDER Date : _____, 2025	7B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS) I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer. 1) _____ 2) _____ 3) _____	7C. MEMBERS OF THE SYNDICATE / SUB - SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA STAMP (Acknowledging upload of Bid in Stock Exchange system)
--	--	--

TEAR HERE

CORONA	CORONA REMEDIES LIMITED BID REVISION FORM - INITIAL PUBLIC OFFER - NR	Acknowledgement Slip for members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agents	Bid cum Application Form No.
---------------	--	---	---

DP ID / CL ID		PAN of Sole / First Bidder	
Additional Amount Blocked (₹ in figures)		ASBA Bank A/c No./UPI ID	
Bank Name & Branch		Stamp and Signature of SCSB branch / members of the Syndicate / Sub-Syndicate Member / Registered Broker / CDP / RTA / Agents	
Received from Mr./Ms./M/s.			
Telephone / Mobile	Email		

TEAR HERE

CORONA REMEDIES LIMITED - BID REVISION FORM - INITIAL PUBLIC OFFER - NR		Option 1	Option 2	Option 3	Stamp & Signature of members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agents	Name of Sole / First Bidder
	No. of Equity Shares					
	Bid Price (₹)					
	Additional Amount Blocked (₹ in figures)					
ASBA Bank A/c No. /UPI ID					Acknowledgement Slip for Bidder	Bid cum Application Form No.
Bank Name & Branch						

Important Note: Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.

TEAR HERE - PLEASE FILL IN BLOCK LETTERS - TEAR HERE - Printed by : www.westernpress.in